Drug Trial News

RSS

$Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS$

Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS

Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.

23 May 2013

GUVAX reports successful results in phase I study of oral, Escherichia coli diarrhea vaccine

The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.

22 May 2013

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

AstraZeneca today presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies.

22 May 2013

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society International Conference in Philadelphia, Pennsylvania.

22 May 2013

Ongoing clinical study to evaluate benefits of high-dose simvastatin for patients with SAH

Can treatment with high doses of a cholesterol-lowering statin drug improve outcomes for patients with stroke caused by rupture and bleeding of brain aneurysms? An ongoing clinical trial will soon find out, according to an article in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

22 May 2013

Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

PuraMed BioScience, Inc., a researcher, developer, and marketer of over-the-counter medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic M, has "robust efficacy".

22 May 2013

Poliovirus vaccine study shows encouraging results in glioblastoma patients

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

22 May 2013

TB clinical drug trials in jeopardy due to federal sequestration funding cuts

Innovative and potentially game-changing clinical trials to develop new drug regimens to prevent and treat tuberculosis, the second leading global infectious disease killer, are in jeopardy due to federal "sequestration" funding cuts.

21 May 2013

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.

From Pfizer, Inc. 21 May 2013

Research explores pharmaceutical advances for IBS, hepatitis C

Research presented at Digestive Disease Week explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea and hepatitis C.

21 May 2013

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

21 May 2013

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

20 May 2013

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

XenoPort, Inc. announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil for the treatment of patients with spasticity due to multiple sclerosis.

20 May 2013

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.

20 May 2013

Patients with treatment-resistant depression benefit from ketamine

Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the Icahn School of Medicine at Mount Sinai.

20 May 2013

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.

18 May 2013

Insero Health announces top-line Phase Ib trial results of INS001 in patients with drug-resistant epilepsy

Insero Health, Inc., a company developing natural compounds to address unmet medical needs in epilepsy and related neurological disorders, is today reporting top-line results from a Phase Ib trial of its lead compound INS001 in patients with drug-resistant epilepsy.

17 May 2013

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3.

17 May 2013

Drug Trial News

Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS

GUVAX reports successful results in phase I study of oral, Escherichia coli diarrhea vaccine

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Ongoing clinical study to evaluate benefits of high-dose simvastatin for patients with SAH

Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

Poliovirus vaccine study shows encouraging results in glioblastoma patients

TB clinical drug trials in jeopardy due to federal sequestration funding cuts

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Research explores pharmaceutical advances for IBS, hepatitis C

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Patients with treatment-resistant depression benefit from ketamine

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Insero Health announces top-line Phase Ib trial results of INS001 in patients with drug-resistant epilepsy

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News